High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 9, 1997, Pages 1953-1956

  Ji, Baohong ^a   Jamet, Pierre ^b   Sow, Samba ^b   Perani, Evelyne G ^a   Traore, Issa ^b   Grosset, Jacques H ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Institut Marchoux Mali   (Mali)

Author keywords

[No Author keywords available]

Indexed keywords

OFLOXACIN; RIFAMPICIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; DRUG MIXTURE; DRUG RESPONSE; FEMALE; HUMAN; LEPROMATOUS LEPROSY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM LEPRAE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT FAILURE;

EID: 0030826560     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.9.1953     Document Type: Article

References (22)

1. Cambau, E., E. Perani, I. Guillemin, P. Jamet, and B. Ji. 1997. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Lancet 349:103-104.
2. Gelber, R. H., and L. Levy. 1987. Detection of persisting Mycobacterium leprae by inoculation of the neonatally thymectomized rat. Int. J. Lepr. 55:872-878.
3. Grosset, J. H., C. C. Guelpa-Lauras, P. Bobin, G. Brucker, J. L. Cartel, M. Constant-Desportes, B. Flageul, M. Frédéric, J. C. Guillaume, and J. Millan. 1989. Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int. J. Lepr. 57:607-614.
4. Grosset, J. H., C. C. Guelpa-Lauras, E. G. Perani, and C. Beoletto. 1988. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int. J. Lepr. 56:259-264.
5. Grosset, J. H., B. Ji, C. C. Guelpa-Lauras, E. G. Perani, and L. N. N'Deli. 1990. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int. J. Lepr. 58:281-295.
6. Jamet, P., L. Blanc, O. C. Faye, I. Traore, and P. Bobin. 1994. Relapses after a single dose of rifampin in skin-smear negative multibacillary patients after dapsone monotherapy. Int. J. Lepr. 62:209-214.
7. Jamet, P., B. Ji, and the Marchoux Chemotherapy Study Group. 1995. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Int. J. Lepr. 63:195-201.
8. Ji, B. 1985. Dapsone resistance in leprosy - a review. Lepr. Rev. 56:265-278.
9. Ji, B. 1987. Drug susceptibility testing of Mycobacterium leprae. Int. J. Lepr. 55:823-829.
10. Ji, B., P. Jamet, E. C. Perani, P. Bobin, and J. H. Grosset. 1993. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J. Infect. Dis. 168:188-190.
11. Ji, B., P. Jamet, E. G. Perani, S. Sow, C. Lienhardt, C. Petinon, and J. H. Grosset. 1996. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob. Agents Chemother. 40:2137-2141.
12. Ji, B., E. G. Perani, C. Petinom, and J. H. Grosset. 1996. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob. Agents Chemother. 40:393-399.
13. Ji, B., E. G. Perani, C. Petinom, L. N'Deli, and J. H. Grosset. 1994. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob. Agents Chemother. 38:662-667.
14. Levy, L., C. C. Shepard, and P. Fasal. 1976. The bactericidal effect of rifampin on M. leprae in man: (a) single dose of 600, 900 and 1200 mg; and (b) daily doses of 300 mg. Int. J. Lepr. 44:183-187.
15. Marchoux Chemotherapy Study Group. 1992. Relapse in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Int. J. Lepr. 60:525-535.
16. Ridley, D. S., and W. H. Jopling. 1966. Classification of leprosy according to immunity: a five group system. Int. J. Lepr. 34:255-273.
17. Shepard, C. C. 1960. The experimental disease that follows the injection of human leprosy bacilli into footpads of mice. J. Exp. Med. 112:445-454.
18. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. 1987. Persisting Mycobacterium leprae among THELEP trial patients in Bamako and Chingleput. Lepr. Rev. 58:325-337.
19. Traore, I., B. Ji, C. Lienhardt, P. Bobin, and J. H. Grosset. 1996. Determination of the minimal effective dosages of ofloxacin and sparfloxacin against M. leprae in the mouse foot pad system. Int. J. Lepr. 64:142-145.
20. World Health Organization. 1996. Progress towards the elimination of leprosy as a public health problem. WHO Wkly. Epidemiol. Rec. 20:149-156.
21. World Health Organization Study Group. 1982. Chemotherapy of leprosy for control programmes. WHO technical report series no. 675. World Health Organization, Geneva, Switzerland.
22. World Health Organization Study Group. 1994. Chemotherapy of leprosy. WHO technical report series no. 847. World Health Organization, Geneva, Switzerland.